Other Stories

Financial regulator asks prosecutors to launch probe into Samsung BioLogics Updated: 2018-11-21 04:20:15 KST

Seoul's financial regulator formally asked state prosecutors to launch a criminal probe into the accounting practices of Samsung BioLogics, the biopharmaceutical arm of Samsung Group, on Tuesday.
This comes after the Securities and Futures Commission suspended trading of Samsung BioLogics' shares on the benchmark KOSPI last week for intentionally breaching accounting standards.
The company is also subject to punitive examination for delisting.
The regulator argued Samsung BioLogics had inflated its value by nearly 4-billion U.S. dollars in 2015 by changing the method used to calculate its majority stake in Samsung Bioepis, its unlisted partner.
Samsung has denied any wrongdoing.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.